Abiomed

Devices & Diagnostics

Heroes in our midst: MedTech Vets program trains soldiers for civilian jobs in medical device industry

Fourteen veterans will endure a different kind of bootcamp this week: one that helps prepare them for jobs in the medtech industry. The AdvaMed Medical Technology Veterans Program Bootcamp kicked off yesterday and runs through Sept. 24 in Washington, D.C. The program helps selected veterans apply skills built on the battlefield to civilian job applications, […]

presented by
Devices & Diagnostics

‘World’s smallest heart pump’ company lands big government contract with VA

The product Abiomed (ABMD) has deemed to be the “world’s smallest heart pump” will be included on the Veterans Affairs‘ Federal Supply Schedule. The Danvers, Mass.-based announced today it’s landed a federal contract to make its Impella platform available through an automated online database to about 169 VA’s facilities and 42 Department of Defense hospitals in […]

Devices & Diagnostics

Abiomed shares slip after FDA warning letter

Shares of Abiomed Inc. (NSDQ:ABMD) slipped nearly five percent on Wall Street this morning, after the FDA posted a warning letter admonishing the heart pump maker for marketing a device for uses it’s not cleared for. The federal watchdog agency said a May 12 review of Danvers, Mass.-based Abiomed’s advertising, product labels and website “indicate […]

MedCity Influencers

Abiomed pulls plug on Impella heart pump study

Over-ambitious doctors seem to have prompted Abiomed Inc. (NASDAQ:ABMD) to close down a clinical trial of its flagship cardiac assist device. The Danvers, Massachusetts-based company pulled the plug on the Protect II trial of its Impella 2.5 heart pump "based on a futility determination at the planned interim analysis regarding the primary end-point, which the company views as likely to be due to unanticipated confounding variables related to the use of rotational atherectomy."

MedCity Influencers

Medtronic, Stryker, Abiomed CEOs talk devices

The CEOs of three medical device makers sat down for a round-table discussion of the challenges and opportunities facing the industry at the annual AdvaMed MedTech conference in Washington, D.C. William Hawkins of Medtronic Inc. (NYSE:MDT), Stephen MacMillan of Stryker Corp. (NYSE:SYK) and Michael Minogue of Abiomed Inc. (NASDAQ:ABMD) spoke about upcoming changes to the 510(k) protocol, the user fee program, transparency initiatives and the steps they're taking to deal with healthcare reform.

MedCity Influencers

Abiomed proselytizing for heart pumps

Abiomed Inc. (NSDQ:ABMD) started a new education program for hospitals. The Danvers, Massachusetts-based company is selecting healthcare institutions to be training centers for its Impella cardiac assist devices. Abiomed wants hospitals to adopt protocols that include the early administration of its heart pumps for patients with distressed hearts. Abiomed said use of its devices reduces […]

sponsored content

A Deep-dive Into Specialty Pharma

A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.